Literature DB >> 24644540

Amyloid A amyloidosis: frequently neglected renal disease in injecting drug users.

Ali Nayer1.   

Abstract

Implication for health policy/practice/research/medical education: Amyloid A (AA) amyloidosis is a systemic form of amyloidosis secondary to chronic infections and inflammatory disorders such as recurrent suppurative skin infections secondaryto subcutaneous administration of drugs (skinpopping).The diagnosis of AA amyloidosis is frequently overlooked due to the insidious nature of the disease. The renal manifestations of AA amyloidosis include proteinuria, tubular dysfunction, and progressive loss of renal function. Urinalysis and quantification of urinary protein excretion are important screening tests. Early diagnosis and treatment of AA amyloidosis can reverse end-organ damage.

Entities:  

Keywords:  Amyloid A amyloidosis; Skin-popping; Subcutaneous drug injection; Suppurative skin infections

Year:  2013        PMID: 24644540      PMCID: PMC3956904          DOI: 10.12860/jnp.2014.06

Source DB:  PubMed          Journal:  J Nephropathol        ISSN: 2251-8363


  9 in total

Review 1.  Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review.

Authors:  Bradley M Mathers; Louisa Degenhardt; Benjamin Phillips; Lucas Wiessing; Matthew Hickman; Steffanie A Strathdee; Alex Wodak; Samiran Panda; Mark Tyndall; Abdalla Toufik; Richard P Mattick
Journal:  Lancet       Date:  2008-09-23       Impact factor: 79.321

Review 2.  Acute-phase proteins and other systemic responses to inflammation.

Authors:  C Gabay; I Kushner
Journal:  N Engl J Med       Date:  1999-02-11       Impact factor: 91.245

3.  Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.

Authors:  J D Gillmore; L B Lovat; M R Persey; M B Pepys; P N Hawkins
Journal:  Lancet       Date:  2001-07-07       Impact factor: 79.321

4.  Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever.

Authors:  D Zemer; M Pras; E Sohar; M Modan; S Cabili; J Gafni
Journal:  N Engl J Med       Date:  1986-04-17       Impact factor: 91.245

5.  Serum amyloid A  renal amyloidosis in a chronic subcutaneous ("skin popping") heroin user.

Authors:  Chad Cooper; Jorge E Bilbao; Sarmad Said; Haider Alkhateeb; Jorge Bizet; Ahmed Elfar; Olinamyr Davalos; Ana T Meza; German T Hernandez
Journal:  J Nephropathol       Date:  2013-07-01

Review 6.  Clinical and therapeutic aspects of AA amyloidosis.

Authors:  B P Hazenberg; M H van Rijswijk
Journal:  Baillieres Clin Rheumatol       Date:  1994-08

7.  Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component.

Authors:  P N Hawkins; J P Lavender; M B Pepys
Journal:  N Engl J Med       Date:  1990-08-23       Impact factor: 91.245

8.  Renal amyloidosis in a drug abuser.

Authors:  A U Tan; A H Cohen; B S Levine
Journal:  J Am Soc Nephrol       Date:  1995-03       Impact factor: 10.121

9.  Natural history and outcome in systemic AA amyloidosis.

Authors:  Helen J Lachmann; Hugh J B Goodman; Janet A Gilbertson; J Ruth Gallimore; Caroline A Sabin; Julian D Gillmore; Philip N Hawkins
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

  9 in total
  2 in total

1.  Amyloid A amyloidosis with subcutaneous drug abuse.

Authors:  Jair Munoz Mendoza; Vasil Peev; Mario A Ponce; David B Thomas; Ali Nayer
Journal:  J Renal Inj Prev       Date:  2013-11-02

2.  Recognizing Skin Popping Scars: A Complication of Illicit Drug Use.

Authors:  Rachael C Saporito; Mildred A Lopez Pineiro; Micheal R Migden; Sirunya Silapunt
Journal:  Cureus       Date:  2018-06-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.